ADAM10 and ovarian carcinoma: Preventing the production of sBCAM by blocking ADAM10 and/or other relevant metalloproteinases may also represent an option, but is less likely to succeed in view of the failure of marimastat in clinical trials, including ovarian cancer.79, 80